{'fraction_non_alphanumeric': 0.028241335044929396, 'fraction_numerical': 0.01668806161745828, 'mean_word_length': 5.341463414634147, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Absence of BRAF V600E in non‐infiltrative, non‐invasive follicular variant of papillary thyroid carcinoma

So does the completely negative staining in normal epithelium in a quarter of cases. In daily routine, AMACR is the most widely used marker to stain neoplastic prostate epithelium. Compared to GSTpi, which stains 99% of tumour cells with less intensity than the surrounding normal epithelium, both markers show a high sensitivity. GSTpi showed diagnostically useful negativity in 95% of the 21 cases (3.4%) that were AMACR-negative. Particularly in this setting, GSTPi may be useful as an additional adjuvant marker. However, in 25% of cases GSTpi negativity was less specific in identifying neoplastic epithelium with benign secretory cells also lacking immunoreactivity.